Abstract
Methysergide, 2-methyl lysergic acid butanolamide (UML-491 ),8 is considered to be the most potent serotonin antagonist available at the present time. It has consistently shown maximum antiserotonin activity against serotonin edema induced in rheumatoid patients and maximally inhibited the bronchospasm induced in guinea pigs by serotonin aerosol(2). A fair degree of correlation has been reported to exist between the central serotonin antagonist activity of the phenothiazines and their tranquilizing activity in laboratory animals(3, 4). The benzyl analogue of serotonin, BAS, an entirely different type of compound with a definite antiserotonin effect, was evaluated in a group of chronic psychotic female patients, and the most prominent beneficial action seen in 22 of 24 patients was that of tranquilization(2). However, at least one serotonin antagonist, BOL-148, has shown no tranquilizing activity although some sedative value has been attributed -to it(1). RESEARCH DESIGN In view of these divergent findings, it was decided to investigate this area further on a clinical level. Under double-blind conditions, effects of the new compound methysergide (UML-491) were contrasted with effects of placebo and chiorpromazine in a group of chronic schizophrenics who had been off all medications for at least 60
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
